HSTC HST Global, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 797564 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY30.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.7%
ROA-15.8%
ROIC (approx.)-23.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets3.3%
Debt / equity0.00x
Current ratio0.25x
Interest coverage-28.94x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 | FY20192019-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| SG&A expense | $20,907 | $21,035 | $25,718 | $27,978 | $71,348 |
| Operating income | -$140,907 | -$141,035 | -$145,718 | -$207,978 | -$151,554 |
| Interest expense | $5,303 | $4,039 | $2,642 | $1,014 | $17,874 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$146,210 | -$145,074 | -$148,360 | -$208,992 | $426,572 |
| EPS (basic) | -0.03 | -0.03 | -0.03 | -0.04 | 0.13 |
| EPS (diluted) | — | — | -0.03 | -0.04 | 0.13 |
| Weighted avg. shares (diluted) | — | — | 5.25M | 4.77M | 3.27M |
| Balance sheet | |||||
| Cash & equivalents | $1,526 | $190 | $225 | $660 | $1,955 |
| Current assets | $1,526 | $190 | $225 | $660 | $1,955 |
| Intangibles | $0 | — | — | — | — |
| Total assets | $1,526 | $190 | $225 | $660 | $1,955 |
| Current liabilities | $593,593 | $446,047 | $301,008 | $153,083 | $5,385 |
| Total liabilities | $593,593 | $446,047 | $301,008 | $153,083 | $5,385 |
| Shareholders' equity | -$592,067 | -$445,857 | -$300,783 | -$152,423 | -$3,430 |
| Shares outstanding | 5.25M | 5.25M | 5.25M | 5.25M | 4.25M |
| Cash flow statement | |||||
| Operating cash flow | -$20,906 | -$21,035 | -$29,836 | -$26,971 | -$91,905 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $22,242 | $21,000 | $29,401 | $25,676 | $93,860 |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.